Related Experiment Video

Updated: Mar 23, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.3K

Direct Oral Anticoagulants in Cirrhosis

Nicolas M Intagliata1, Hillary Maitland2, Stephen H Caldwell3

  • 1Division of Gastroenterology and Hepatology, Center for Coagulation in Liver Disease, University of Virginia Medical Center, PO Box 800708, Charlottesville, VA, USA. intagliata@virginia.edu.

Current Treatment Options in Gastroenterology
|March 30, 2016
PubMed

Insights

Patients with chronic liver disease and cirrhosis face thrombosis risks. While traditional anticoagulants are used, direct oral anticoagulants (DOACs) show promise in compensated cirrhosis, though more research is needed.

Area of Science:

  • Hepatology and Thrombosis Research
  • Pharmacology of Anticoagulation in Liver Disease

Background:

  • Increasing recognition of thrombosis risk in chronic liver disease (CLD) patients.
  • Cirrhosis patients often require anticoagulation for conditions like VTE, PVT, and AF.
  • Limited evidence complicates anticoagulant selection for CLD patients.

Purpose of the Study:

  • To review current practices and emerging data on anticoagulation in cirrhosis.
  • To discuss the role and safety of direct oral anticoagulants (DOACs) in this population.
  • To highlight the need for further research on anticoagulation in cirrhosis.

Main Methods:

  • Review of existing literature and clinical practice guidelines.
  • Analysis of emerging data on DOACs in patients with liver disease.
  • Discussion of the pharmacologic properties and safety profiles of anticoagulants.

Main Results:

  • Traditional anticoagulants (LMWH, VKAs) are used in select compensated cirrhosis patients.
  • DOACs offer advantages like oral administration and no routine monitoring.
  • Emerging data suggest DOACs may be safe and effective in well-compensated cirrhosis.

Conclusions:

  • Anticoagulation in cirrhosis presents unique challenges due to limited trial data.
  • DOACs are a potential option for anticoagulation in compensated cirrhosis.
  • Further comprehensive studies are essential to confirm safety and efficacy of all anticoagulants in cirrhotic patients.
Abstract

Keywords:
BleedingDirect oral anticoagulantsFactor XaHeparinPortal veinThrombinThrombosisWarfarin

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

1.8K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
744